 <h1>Congratulations! 🎉 </h1>
    <p style="color:#637381;">All done! You’ve completed another milestone.</p>

To continue, enter your details to log in.

We’ve sent a 6‑digit code to #MAIL_ADDRESS#\nPlease check your inbox or spam folder and enter the code below to continue.

Verification code sent

Thank you for the payment. You can now access {collectionName} by simply clicking the button below.

Yes, you’ve successfully ordered! 🎉

Unlock This Exclusive Course

It seems that your email address is not currently on the authorized access list. Please ensure you are using the email address that was invited, or contact the content owner for assistance.

Verification Required for Access

Course Introduction and Overview

What is this course about?

Who is this mini-course for?

Teaching Goals

Copy of Teaching Goals

Core Concepts: Specificity vs. Selectivity Pathways

Concept Simplified

Three ways ICH Q2(R2), Section 3.1.1, lets you demonstrate this:

Practical Application and Risk Management

Case Study with Characters and Dialogue

Step-by-step actions for a specificity/selectivity study:

Risk Indicators to Watch For:

Audit Readiness and Documentation Best Practices

10 Key-Point Audit Checklist — Specificity/Selectivity

Summary: Top 5 Takeaways

Knowledge Assessment (Quiz)

Question 1

Question 2

Question 3

Question 4

Question 5

Reflection and Feedback

Part B — Reflection 'What would you implement tomorrow?'

Course Evaluation and Feedback

Welcome to "Applying ICH Q2(R2) Requirements for Specificity and Selectivity," a comprehensive online course designed for analytical scientists, quality assurance professionals, and regulatory affairs specialists. In the highly regulated pharmaceutical industry, ensuring patient safety relies heavily on the accurate identification and quantitation of active pharmaceutical ingredients and impurities.

Welcome to "Applying ICH Q2(R2) Requirements for Specificity and Selectivity," a comprehensive online course designed for analytical scientists, quality assurance professionals, and regulatory affairs specialists. In the highly regulated pharmaceutical industry, ensuring patient safety relies heavily on the accurate identification and quantitation of active pharmaceutical ingredients and impurities. This course dives deep into the updated ICH Q2(R2) guidelines, specifically focusing on Section 3.1.1, to help you master the critical distinctions between specificity and selectivity.

Throughout this training, you will explore the three primary pathways for demonstrating specificity and selectivity: absence of interference, orthogonal procedure comparison, and technology-inherent justification. We will guide you through practical applications, including forced degradation studies, handling co-eluting peaks, and investigating Out of Specification (OOS) or Out of Trend (OOT) results tied to matrix interference.

Beyond theoretical concepts, this course emphasizes real-world risk management and audit readiness. You will gain access to a robust 10-point audit checklist to ensure your validation reports are fully defensible during FDA, EMA, or other health authority inspections. By the end of this program, you will possess the expertise to design robust experimental protocols, critique analytical data summaries, and build cohesive, regulatory-compliant narratives within CTD Module 3. Elevate your analytical lifecycle management skills and ensure your laboratory's compliance with the latest global standards.

Applying ICH Q2(R2) Requirements for Specificity and Selectivity

<div class="simple-box-wrapper">
    <div class="simple-box">
        <div class="column">
            <p>Ensuring the unequivocal identification and accurate quantitation of analytes within complex matrices is a cornerstone of pharmaceutical quality control and patient safety. Under the revised ICH Q2(R2) guideline, the regulatory expectations for demonstrating specificity and selectivity have been distinctly delineated, requiring analytical and quality professionals to adopt highly rigorous validation strategies. This program provides a comprehensive examination of these updated requirements, addressing the critical responsibilities of analysts, quality assurance personnel, and regulatory affairs staff in defending method specificity. By mastering these foundational concepts, cross-functional teams can effectively assemble robust CTD Module 3.2.S.4/P.5 validation summaries, evaluate cross-departmental impacts, and confidently navigate Out of Specification (OOS) or Out of Trend (OOT) investigations tied to matrix interference.</p>

<p>The curriculum systematically progresses from the theoretical differentiation of specificity and selectivity pathways to the practical execution of absence-of-interference studies and forced-degradation challenges. Participants will explore the three primary pathways permitted under Section 3.1.1 of the guideline, including orthogonal procedure comparisons and scientifically justified technology-inherent claims. Furthermore, the program emphasizes proactive risk management and audit readiness, equipping professionals with a comprehensive 10-point audit checklist to evaluate validation reports against stringent regulatory standards. By bridging the gap between regulatory theory and laboratory application, this training ensures that analytical data summaries remain fully defensible during FDA, EMA, or other health authority inspections, thereby safeguarding the integrity of long-term analytical lifecycle management.</p>
        </div>
    </div>
</div>
